European Journal

of Clinical Pharmacology

Volume 64 ■ Number 5 • May 2008

CLINICAL TRIAL

Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil

D.-H. Choi ■ W.-G. Shin ■ J.-S. Choi 445

SPECIAL ARTICLE

A nurse-led intervention for identification of drug-related problems

M, Bergqvist ■ J. Ulfvarson ■ E. Andersen Karlsson ■ C von Bahr 451

PHARMACODYNAMICS

The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects

J.M. Kovarik ■ M. Lu ■ G.-J. Riviere ■ I. Barbet ■ S. Maton ■ D.R. Goldwater ■ R.L. Schmouder 457

PHARMACOGENETICS

The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements

A. Gaedigk ■ C. Coetsee 465

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extra pyramid a I side effects in male schizophrenic patients

A. Gunes ■ M.-L Dahl ■ E. Spina ■ M.G. Scordo 477

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and W-des methyl venlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele

M. Hermann • M. Hendset ■ K. Fosaas ■ M. Hjerpset ■ H. Refsum 483

Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers

T. Niioka -M. Miura -T. Uno ■ N. Yasui-Furukori ■ M. Hayakari T.Tateishi • T.Suzuki 503

Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo

MJ. Karjaiainen ■ PJ. Neuvonen ■ J.T. Backman 511

Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops

K. Abduljalil ■ M. Diestelhorst ■ 0. Doroshyenko ■ A. Lux ■ A. Steinfeld • S. Dinslage ■ R. Suverkrup ■ U. Fuhr 521

PHARMACOEPIDEMIOLOGY AND PRESCRIPTION

The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports

HJ. Derijks ■ R.H.B. Meyboom ■ E.R. Heerdink ■ F.H.P. De Koning R. Janknegt ■ M. Lindquist ■ A.C.G. Egberts 531

Ten years after the Dutch public health campaign on folic acid: the continuing challenge

H.E.K. de Walle ■ L.T.W. de Jong-van den Berg 539

Predictors of orphan drug approval in the European Union

H.E. Heemstra ■ R.L de Vrueh ■ S. van Weely ■ H.A. Buller ■ H.G.M. Leufkens 545

LETTER TO THE EDITOR

Detection of the pharmaceutical agent glaucine as a recreational drug

P.I. Dargan ■ J. Button ■ L Hawkins ■ J.R.H. Archer ■ H. Ovaska ■ S. Lidder ■ J. Ramsey ■ D.W. Holt ■ D.M. Wood 553

PHARMACOKINETICS AND DISPOSITION

Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients

A. Ferrari ■ D. Pinetti ■ A. Bertolini ■ C. Coccia ■ E. Sternieri

Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

K. Moksnes ■ O.M. Fredheim ■ P. Klepstad ■ S. Kaasa ■ A. Angelsen-T. Nilsen -0. Dale 497

489

Further articles can be found at Indexed in/abstracted by Current Contents and Index Medicus.

Instructions for Authors for EurJClin Pharmacol ate available at